• Eng
  • 中文
  • 日本語
  • Span
  • Eng
  • 中文
  • 日本語
  • Span
Menú
Buscar estudios clínicos
Volver a los resultados de la búsqueda
Estará reclutando
ID del estudio de Astellas
7517-CL-1101

Gene transfer study in patients with late onset Pompe disease

ID del estudio de Astellas
7517-CL-1101
Id. de ClinicalTrials.gov
NCT04837196
EU CTIS ID
N/A
jRCT ID
N/A
CN CDE ID
N/A
Obtenga más información

Resumen del estudio

The purpose of this study is to evaluate the safety, tolerability, and clinical response of ASP7517, and determine the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose (MTD) of ASP7517 when administered as a single agent and in combination with pembrolizumab.

This study will also evaluate other measures of anticancer activity of ASP7517 when administered as a single agent and in combination with pembrolizumab based on central and local assessment.

Más información del estudio

Fase
Phase 1/Phase 2
Producto
  • ASP7517
  • Pembrolizumab
    • Producto
    ASP7517
    Tipo
    Interventional
    Enmascaramiento
    None (Open Label)
    Número de inscripción
    385
    Mostrar más información del estudio

    Who May Participate

    Every clinical study has its own set of rules for who can join, known as eligibility criteria. These might cover things like your age, gender, general health, the type and stage of your condition, and your past treatments. But, only the study team can decide if you’re a good fit to take part.

    What to expect

    If the study is right for you, and you’d like to join, you will be randomly assigned to receive either one of the study medications or a placebo. In this study, 4 out of 5 people will receive a study medicine and 1 out of 5 people will receive a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Whilst you are free to leave the study at any time, staying in a study until the end really helps scientists and doctors to discover new treatments for people living with eczema.

    Timer icon
    Length of study treatment
    10 Months
    Coin icon
    Number of study visits
    Approximately 13

    Trial purpose

    In a world where innovation meets care, we invite you to explore the possibilities of groundbreaking treatments. Imagine a scenario where you could be part of a journey that transforms lives.

    Picture this: 80% of participants will receive a revolutionary treatment, while 20% will experience a placebo that mirrors the real thing. Your involvement could pave the way for new discoveries in eczema care. Remember, you can opt out at any moment, but your commitment until the end can significantly contribute to the advancement of medical science.

    Study documents

    Plain Language Summary
    Available Languages: English
    Descargar documento(s)
    Protocol
    Available Languages: English
    Descargar documento(s)
    Protocol and Statistical Analysis Plan
    Available Languages: English
    Descargar documento(s)
    Clinical Study Report
    Available Languages: English
    Descargar documento(s)
    Press Release
    Available Languages: English
    Descargar documento(s)

    Obtenga más información

    ¿Le gustaría obtener más información sobre los centros del estudio clínico que están reclutando a participantes para el estudio Study of ASP7517 Alone and with Pembrolizumab in Participants with Advanced Solid Tumors Expressing WT1 Antigen? Comuníquese con nosotros completando sus datos a la derecha y le responderemos.

    • A caregiver
    • A healthcare provider
    • A parent
    • A patient
    • A patient advocate
    • Alemania
    • Anteriormente Serbia y Montenegro
    • Arabia Saudita
    • Argelia
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Bélgica
    • Bielorrusia
    • Bosnia y Herzegovina
    • Brasil
    • Bulgaria
    • Canadá
    • Chile
    • China
    • Colombia
    • Croacia
    • Dinamarca
    • Egipto
    • Eslovaquia
    • Eslovenia
    • España
    • Estados Unidos
    • Estonia
    • Federación de Rusia
    • Filipinas
    • Finlandia
    • Francia
    • Georgia
    • Grecia
    • Guatemala
    • Hong Kong
    • Hungría
    • India
    • Indonesia
    • Irlanda
    • Islandia
    • Israel
    • Italia
    • Japón
    • Jordania
    • Kazajistán
    • Letonia
    • Líbano
    • Lituania
    • Macedonia
    • Malasia
    • Marruecos
    • México
    • Montenegro
    • Noruega
    • Nueva Zelanda
    • Países Bajos
    • Panamá
    • Perú
    • Polonia
    • Portugal
    • Puerto Rico
    • Reino Unido
    • República Checa
    • República de Corea
    • República de Moldavia
    • República Dominicana
    • Rumania
    • Serbia
    • Singapur
    • Sudáfrica
    • Suecia
    • Suiza
    • Tailandia
    • Taiwán, provincia de China
    • Turquía
    • Ucrania
    • Vietnam

    Al hacer clic en [“Continuar/Enviar”], usted acepta que Astellas se comunique con usted por correo electrónico con información que lo ayude a conectarse con los centros de estudios clínicos. Si bien podemos conectarlo con los centros de estudios clínicos, no podemos responder preguntas sobre ningún tratamiento en investigación por correo electrónico. Su consentimiento para recibir correos electrónicos no es un requisito para participar en un estudio o estudio clínico. Para obtener más información, incluida la forma de cancelar la suscripción en cualquier momento, consulte nuestro Aviso de privacidad y política de cookies.

      Ubicaciones

      No se encontraron ubicaciones.
      Información del estudio
      Estudio de seguimiento
      Edad
      18 años de edad en adelante
      Afección
    • Cáncer avanzado/metastásico
      • Sexo
      Mujer y hombre
      Fechas del estudio
      Jul 2021 - Nov 2027
      Más información del estudio
      Criterios de inclusión
      • Participant has locally-advanced (unresectable) or metastatic solid tumor malignancy that is confirmed by available pathology records or current biopsy. Participant must also have received all standard therapies (unless the therapy is contraindicated or intolerable) appropriate to provide clinical benefit for his/her specific tumor type. However, participants with metastatic melanoma who have not received checkpoint inhibitors [CPIs] (i.e., CPIs naive) may enroll in the Phase 2 Combination Therapy Arm Dose Expansion Cohort to receive CPI: Pembrolizumab.
      • Participant must be diagnosed with solid tumor known to express WT1 antigen such as, but not limited to melanoma, ovarian cancer or Colorectal Cancer (CRC).
      • Participant consents to provide an archival tumor specimen in a tissue block or unstained serial slides, if available, prior to study treatment.
      • Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
      • Participant’s last dose of prior antineoplastic therapy, including any immunotherapy, was 21 days or 5 half-lives, whichever is shorter, prior to initiation of IP administration. A participant with BRAF gene, epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation positive non-small cell lung carcinoma is allowed to remain on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or anaplastic lymphoma kinase (ALK) or BRAF inhibitor therapy until 4 days prior to the start of Investigational Product (IP) administration.
      • Participant has completed any radiotherapy (including stereotactic radiosurgery) at least 2 weeks prior to IP administration.
      • Participant’s Adverse Events (AEs) (excluding alopecia) from prior therapy have improved to grade 1 or baseline within 14 days prior to start of IP.
      • Participant has adequate organ function prior to start of IP. If a participant has received a recent blood transfusion, the laboratory tests must be obtained ≥ 4 weeks after any blood transfusion.
      • A female participant is eligible to participate if she is not pregnant and at least 1 of the following conditions applies:
        • Not a woman of childbearing potential (WOCBP) OR
        • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 6 months after the final IP administration.
      • Female participant must agree not to breastfeed starting at screening and throughout the IP and for 180 days after the final IP administration.
      • Female participant must not donate ova starting at screening and throughout the IP and for 180 days after the final IP administration.
      • A male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for at least 180 days after the final IP administration.
      • Male participant must not donate sperm during the treatment period and for 180 days after the final IP administration.
      • Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 180 days after the final IP administration.
      • Participant agrees not to participate in another interventional study while receiving IP.

        • Additional Inclusion Criteria for Participants in the Expansion Cohorts:

      • Participant meets one of the following:
        • Participant has the tumor type for which a confirmed response was observed in a monotherapy or combination therapy dose escalation (for melanoma, ovarian cancer and Colorectal Cancer [CRC] only) cohort; OR
        • For tumor specific expansion cohorts of ASP7517 or ASP7517 with pembrolizumab, participant has the applicable tumor type melanoma, ovarian cancer, CRC.
      • Participant has at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1. Las lesiones situadas en un área previamente irradiada se consideran medibles si se ha demostrado progresión en dichas lesiones.
      • Participant consents to provide a tumor specimen in a tissue block or unstained serial slides obtained within 56 days prior to first dose of IP. If a recent tissue sample cannot be provided due to medical or safety concerns, enrollment into the study must be discussed with the medical monitor.
      • Participant consents to undergoing a tumor biopsy (core tissue biopsy or excision) during the treatment period as indicated in the schedule of assessments.
      Criterios de exclusión
      • Participant weighs < 45 kg at screening.
      • Participant has received investigational therapy (other than an investigational EGFR TKI in a participant with EGFR activating mutations or ALK or BRAF inhibitor in a participant with an ALK mutation) within 21 days or 5 half-lives, whichever is shorter, prior to start of IP.
      • Participant requires or has received systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to Cycle 1 Day 1. Participants using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone up to 10 mg per day of prednisone) are allowed.
      • El participante tiene metástasis sintomáticas en el sistema nervioso central (SNC) o el participante tiene evidencia de metástasis inestables en el SNC incluso si es asintomático (por ejemplo, progresión en los rastreos). Participants with previously treated CNS metastases are eligible, if they are clinically stable and have no evidence of CNS progression by imaging for at least 4 weeks prior to start of IP and are not requiring immunosuppressive doses of systemic steroids (> 30 mg per day of hydrocortisone or > 10 mg per day of prednisone or equivalent) for longer than 2 weeks.
      • Participant has an active autoimmune disease. Participants with type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy or skin disorders (e.g., vitiligo, psoriasis or alopecia) not requiring systemic treatment are allowed.
      • Participant was discontinued from prior immunomodulatory therapy due to a grade ≥ 3 toxicity that was mechanistically related (e.g., immune related) to the agent.
      • Participant has known history of serious hypersensitivity reaction to a known ingredient of ASP7517 or pembrolizumab or severe hypersensitivity reaction to treatment with another monoclonal antibody.
      • Participant has a known history of human immunodeficiency virus.
      • Participant with known history of positive hepatitis B surface antigen or isolated hepatitis B core antibody (including acute HBV or chronic HBV) or hepatitis C ([HCV] ribonucleic acid [RNA] detected by qualitative assay). Hepatitis C RNA testing is not required in participants with negative hepatitis C antibody testing.
      • Participant has received a live vaccine against infectious diseases within 28 days prior to initiation of IP.
      • Participant has a history of drug-induced pneumonitis (interstitial lung disease), a history of (non-infectious) pneumonitis that required steroids, radiation pneumonitis or currently has pneumonitis.
      • Participant has an infection requiring systemic therapy within 14 days prior to IP.
      • Participant has received a prior allogeneic bone marrow or solid organ transplant.
      • Participant is expected to require another form of antineoplastic therapy while on IP.
      • Participant has had a myocardial infarction or unstable angina within 6 months prior to the start of IP or currently has an uncontrolled illness including, but not limited to symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
      • Participant has a clinically significant abnormal electrocardiogram at screening.
      • Participant has symptomatic cardiovascular disease within the preceding 12 months unless cardiology consultation and clearance has been obtained for study participation, including but not limited to the following: significant coronary artery disease (e.g., requiring angioplasty or stenting), acute myocardial infarction or unstable angina pectoris < 3 months prior screening, uncontrolled hypertension, clinically significant arrhythmia or congestive heart failure (New York Heart Association grade ≥ 3).
      • Any condition that makes the participant unsuitable for study participation.
      • Participant has had a major surgical procedure and has not completely recovered within 28 days prior to the start of IP.
      • Participant has a prior malignancy active (i.e., requiring treatment of intervention) within the previous 2 years prior to the screening visit, except for locally curable malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast. Participants with organ confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed or treated with definitive radiotherapy.
      • Participant has International Normalized Ration (INR) > 1.5 x Upper Limits of Normal (ULN) and/or activated partial thromboplastin time (aPTT) > 1.5 x institutional normal limits.

        • Additional Exclusion Criteria for Participants in Combination Expansion Cohorts:

      • Participants with metastatic CRC with documented microsatellite instability-high (MSI-H) or mismatch repair (MMR) deficient who have received prior treatment with PD-1 or programmed death-ligand (PD-L1) inhibitors such as nivolumab or pembrolizumab.
      • CPI naïve metastatic melanoma participants who have received PD-1 or PD-L1 inhibitors, such as nivolumab or pembrolizumab.
      • Participants with metastatic ovarian cancer with documented MSI-H or MMR deficient who have received PD-1or PD-L1 inhibitors, such as nivolumab or pembrolizumab.

      Preguntas frecuentes

      ¿Los estudios clínicos son solo para personas con cáncer avanzado?

      Si bien algunos estudios clínicos pueden enfocarse en cánceres más avanzados, muchos estudios están abiertos para pacientes con cáncer en diferentes etapas. Cada estudio tiene reglas que establecen quiénes pueden participar. Por ejemplo, quizás solo puedan participar pacientes de un grupo de edad determinado o aquellos que tengan un tipo determinado de tumor.

      ¿Será necesario que interrumpa mi tratamiento actual para participar en un estudio clínico?

      A veces los investigadores quieren que los participantes sigan recibiendo sus tratamientos actuales durante un estudio clínico. En otras ocasiones, es posible que deba interrumpir sus tratamientos actuales durante un tiempo. Si el tratamiento en investigación no funciona, siempre puede volver a su plan de tratamiento original.

      ¿Debería preocuparme la posibilidad de recibir placebo?

      En los estudios clínicos oncológicos, solo se usa placebo si no hay otro tratamiento disponible para ese tipo de cáncer. Esto ayuda a comparar un tratamiento en investigación con el placebo. Los placebos rara vez se usan en estudios oncológicos, porque en su lugar generalmente se administra el mejor tratamiento disponible, que se denomina “estándar de atención”.

      ¿Necesito una derivación de mi médico para participar en un estudio?

      Es posible que su médico no conozca todas las oportunidades de participación en estudios clínicos que usted tiene a su disposición. Hable con su médico o con otro profesional de la salud sobre la información que encuentre en relación con un estudio clínico. Podrán ayudarlo a decidir si el estudio clínico es adecuado para usted. Si no encuentra ninguna opción en este sitio web, le recomendamos que visite un registro público en línea, por ejemplo, clinicaltrials.gov para conocer los diversos estudios clínicos que están disponibles.

      Seguir leyendo

      1

      ¿Qué son los estudios clínicos?

      Encuentre un estudio
      2

      ¿Por qué son importantes los estudios clínicos?

      Más información
      3

      ¿Por qué participar en un estudio clínico?

      Descubra más